Claims for compensation from women with cervical cancer in Norway-A retrospective, descriptive study of a 12-year period.
cervical cancer
claims for compensation
delayed diagnosis
medical failure
Journal
Acta obstetricia et gynecologica Scandinavica
ISSN: 1600-0412
Titre abrégé: Acta Obstet Gynecol Scand
Pays: United States
ID NLM: 0370343
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
16
11
2019
revised:
13
05
2020
accepted:
28
05
2020
pubmed:
4
6
2020
medline:
15
12
2020
entrez:
4
6
2020
Statut:
ppublish
Résumé
In Norway, all patient-reported claims for compensation are evaluated by The Norwegian System of Patient Injury Compensation (NPE). The number of claims from women with cervical cancer is rising, and the approval rate is high. Our aim was to study claims for compensation from women with cervical cancer to identify the type of failures, when, during the time-course of treatment, the medical failures occurred, and the consequences of the failures. A retrospective, descriptive study of claims for compensation to NPE from cervical cancer patients during a 12-year period, from 2007 through 2018. We used anonymized medical expert statements and summaries of NPE cases. In all, 161 women claimed compensation for alleged medical failure related to cervical cancer. Compensation was approved for 100 (62%) women. Mean age at the time of alleged failure was 37.5 years (SD ±9.9). The main reasons why women sought medical attention were routine cervical screening (56%), or vaginal bleeding or discharge (30%). In approved cases, incorrect evaluation of cytology and histology was the cause of most failures (72%). Mean delay of cervical cancer diagnosis for approved cases was 28 months (SD ±22). Treatment not in accordance with guidelines was the cause of failure in 2% of the cases, and failure during follow up was the cause of failure in 12%. Consequences of the failures were as follows: worsening of cancer prognosis (89%), treatment-induced adverse effects, such as loss of fertility (43%) and/or loss of ovarian function in premenopausal women (50%), and permanent injury after chemo-radiation (27%). Seven women (7%) died, most probably as a consequence of the failure. The main cause of medical failure in women with cervical cancer was incorrect pathological diagnosis. The main consequences of failures were worsening of cancer prognosis and treatment-induced adverse effects. Increased focus on the quality of pathological examinations, and better routines in all parts of the cervical examinations might improve patient safety for women in risk of cervical cancer.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1546-1553Informations de copyright
© 2020 Nordic Federation of Societies of Obstetrics and Gynecology (NFOG) Published by John Wiley & Sons Ltd.
Références
Ravlo M, Lieng M, Bukholm IRK, Moen MH, Vanky E. Approved claims for compensation from gynecological patients in Norway-What characterizes the cases? A 14-year nationwide study. Acta Obstet Gynecol Scand. 2019;98:1070-1076.
Cancer in Norway 2017. https://www.kreftregisteret.no/globalassets/cancer-in-norway/2017/cin-2017.pdf (Accessed October 28, 2019)
WHO. Human reproductive program, research for impact| WHO leads the way towards the elimination of cervical cancer as a public health concern. https://www.who.int/reproductivehealth/cervical-cancer-public-health-concern/en/ (Accessed October 28, 2019)
Orumaa M, Leinonen MK, Campbell S, Møller B, Myklebust TÅ, Nygård M. Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016. Int J Cancer. 2019;145:2629-2638.
Kreftregisteret. Fakta om masseundersøkelsen mot livmorhalskreft (cervixscreeningprogrammet). [Facts about mass cervical cancer screening (cervical screening program)]. In Norwegian. https://www.kreftregisteret.no/Generelt/Nyheter/Fakta-om-Masseundersokelsen-mot-livmorhalskreft-eller-Cervixscreeningprogrammet/ (Accessed October 28, 2019)
NIPH. Norwegian Institute of Public Health. HPV vaccine for young women. https://www.fhi.no/en/id/vaccines/hpv-vaccine/ (Accessed October 28, 2019)
Makary MA, Daniel M. Medical error-the third leading cause of death in the US. BMJ. 2016;353:i2139.
Bartlett G, Blais R, Tamblyn R, Clermont RJ, MacGibbon B. Impact of patient communication problems on the risk of preventable adverse events in acute care settings. CMAJ. 2008;178:1555-1562.
Oyebode F. Clinical errors and medical negligence. Med Princ Pract. 2013;22:323-333.
WHO. World alliance for patient safety. Summary of the Evidence on Patient Safety: Implications for Research. https://www.who.int/patientsafety/information_centre/Summary_evidence_on_patient_safety.pdf (Accessed October 28, 2019)
NPE. What are the criteria to qualify for compensation for a patient injury? https://www.npe.no/en/information-compensation-claimants/information-making-application-patient-injury/criteria-to-qualify-for-compensation/ (Accessed October 28, 2019)
Lilleyman J. A blame-free culture in the NHS: quixotic notion or achievable ambition? Perfusion. 2005;20:233.
Bismark MM, Brennan TA, Paterson RJ, Davis PB, Studdert DM. Relationship between complaints and quality of care in New Zealand: a descriptive analysis of complainants and non-complainants following adverse events. Qual Saf Health Care. 2006;15:17-22.
Skjervold SS, Johnsen R, Marhaug G. Documentation and disclosure of adverse events that led to compensated patient injury in a Norwegian university hospital. Int J Qual Health Care. 2015;27:486-491.
Alfsen GC, Chen Y, Kähler H, Bukholm IRK. Pathology-related cases in the Norwegian System of Patient Injury Compensation in the period 2010-2015. Tidsskr Nor Laegeforen. 2016;136:1984-1987.
Kongsgaard UE, Fischer K, Pedersen TE, Bukholm IRK, Warncke T. Complaints to the Norwegian System of Patient Injury Compensation 2001-14 following nerve blockade. Tidsskr Nor Laegeforen. 2016;136:1989-1992.
Spence AR, Goggin P, Franco EL. Process of care failures in invasive cervical cancer: systematic review and meta-analysis. Prev Med. 2007;45:93-106.
Kristiansen I. Dagens Medisin, June 9 2017. Bør kvinner få informasjon om «feiltolkede» livmorhalskreftprøver? [Should women get information on "misinterpreted" cervical cancer tests?] In Norwegian. https://www.dagensmedisin.no/blogger/ivar-sonbo-kristiansen/2017/06/09/bor-kvinner-fa-informasjon-om-feiltolkede-livmorhalskreftprover/ (Accessed October 28, 2019)
Salto-Tellez M, Maxwell P, Halmilton P. Artificial intelligence-the third revolution in pathology. Histopathology. 2019;74:372-376.
Hu L, Bell D, Antani S, et al. An observational study of deep learning and automated evaluation of cervical images for cancer screening. J Natl Cancer Inst. 2019;111:923-932.
Wilson RM. Screening for breast and cervical cancer as a common cause for litigation. BMJ. 2000;320:1352-1353.
Chingang LC, Bischof U, Andall-Brereton G, Razum O. 'Have a Pap smear!'-doctors, their clients, and opportunistic cervical cancer screening. Int J STD AIDS. 2005;16:233-236.
Lim AW, Ramirez AJ, Hamilton W, Sasieni P, Patnick J, Forbes LJ. Delays in diagnosis of young females with symptomatic cervical cancer in England: an interview-based study. Br J Gen Pract. 2014;64:e602-e610.
Koh WJ, Greer BE, Abu-Rustum NR, et al. Cervical Cancer, Version 2.2015. J Natl Compr Canc Netw. 2015;13:395-404.
Norsk gynekologisk forening. Veiledere legeforeningen.no. [Norwegian doctors’ association guides]. In Norwegian. http://legeforeningen.no/Fagmed/Norsk-gynekologisk-forening/Veiledere/ (Accessed October 28, 2019)
Vistad I, Fosså SD, Dahl AA. A critical review of patient-rated quality of life studies of long-term survivors of cervical cancer. Gynecol Oncol. 2006;102:563-572.
Folkehelseinstituttet. Barnevaksinasjonsprogrammet-veileder for helsepersonell. [Child Vaccination Program-Guide for Healthcare Professionals.]. In Norwegian. https://www.fhi.no/nettpub/vaksinasjonsveilederen-for-helsepersonell/vaksinasjon/barnevaksinasjonsprogrammet/#historisk-oversikt (Accessed October 28, 2019)
Folkehelseinstituttet. Fem år etter innføring av HPV vaksine: Stor nedgang i forekomst av HPV. [Five years after the introduction of HPV vaccine: Large decrease in the incidence of HPV.] In Norwegian. https://www.fhi.no/nyheter/2018/fem-ar-etter-innforing-av-hpv-vaksine-stor-nedgang-i-forekomst-av-hpv/ (Accessed October 28, 2019)
Castle PE, Kinney WK, Cheung LC, et al. Why does cervical cancer occur in a state-of-the-art screening program? Gynecol Oncol. 2017;146:546-553.